Gut microbiota in patients with non-alcoholic fatty liver disease
We used a high-throughput amplicon sequencing of 16S rRNA V3-V4 region on the Illumina MiSeq platform, in samples collected from subjects with NAFLD and healthy controls to determine the influence of the gut microbiotas on progression of nonalcoholic liver disease.